This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Su, S.-C.
Right arrow Articles by Chang, F.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Su, S.-C.
Right arrow Articles by Chang, F.-Y.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2008, p. 804-805, Vol. 52, No. 2
0066-4804/08/$08.00+0     doi:10.1128/AAC.01269-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Community-Acquired Liver Abscess Caused by Serotype K1 Klebsiella pneumoniae with CTX-M-15-Type Extended-Spectrum β-Lactamase{triangledown}


arrow
LETTER
 
Klebsiella pneumoniae has emerged as the leading cause of community-acquired pyogenic liver abscess in many countries. Community-acquired pyogenic liver abscess due to K. pneumoniae with a unique antibiogram indicative of resistance only to ampicillin has been demonstrated. We reported the first case on community-acquired pyogenic liver abscess caused by CTX-M-15-type extended-spectrum β-lactamase (ESBL)-producing K. pneumoniae in a man without comorbidity or history of hospitalization.

In August 2006, a previously healthy 39-year-old man experienced a fever with shaking chills for 3 days. Abdominal computed tomography with contrast showed a low-density lesion with a central linear enhancement of about 4.5 cm in liver segment 8. The initial therapy was daily intravenous administration of 2 g ceftriaxone for empirical therapy. Sonography-guided percutaneous drainage of the liver abscess was performed. However, even after 1 week of the aforementioned therapy, a fever with shaking chills remained. Ultimately, Klebsiella pneumoniae was identified in the liver aspirate; susceptibility testing revealed resistance to cefazolin, ceftriaxone, cefotaxime, and cefepime but susceptibility to trimethoprim-sulfamethoxazole, gentamicin, ciprofloxacin, imipenem, and ertapenem. More refined identification confirmed the presence of CTX-M-15-type ESBL-producing K. pneumoniae. Ertapenem (1 g daily) was prescribed. The patient's general condition immediately improved, and the fever abated. The patient was discharged after a 2-week regimen of ertapenem. Oral trimethoprim-sulfamethoxazole for sequential treatment was prescribed according to the antibiogram of the K. pneumoniae. He remained well at a 6-month follow-up.

This strain of serotype K1 CTX-M-15 ESBL-producing K. pneumoniae differed from strains causing community-acquired liver abscess with respect to the antibiogram pattern, the pulsed-field gel electrophoresis pattern (Fig. 1), and treatment (1, 3). The capsular serotype was determined with a capsular swelling test and countercurrent immunoelectrophoresis (3). The ESBL CTX-15 was detected by PCR amplification with a previous method (2). The primers used for the blaCTX-M-15 gene were CTX-F (5'-GGTTAAAAAATCACTGCGTC-3') and CTX-R (5'-TTGGTGACGATTTTAGCCGC-3'). Sequencing was done with corresponding primers specific for the blaCTX-M gene. The sequence was compared with that in the GenBank nucleotide database under accession no. AY044436 at http://www.ncbi.nlm.nih.gov/BLAST/. Multidrug-resistant strains of K. pneumoniae including ESBL have not been identified as the cause of community-acquired liver abscess.


Figure 1
View larger version (13K):
[in this window]
[in a new window]

  		FIG. 1. Dendrogram based on pulsed-field gel electrophoresis of nine clinical K. pneumoniae isolates. No. 12, 13, 21, 25, 27, 71, and 72 were isolated from community-acquired liver abscess of serotype K1; no. 10 was isolated from nosocomial liver abscess of ESBL-producing non-K1/K2; no. 27-2 is the present strain isolated from community-acquired liver abscess of ESBL-producing serotype K1.

ESBL strains of K. pneumoniae are common causes of nosocomial bacteremia, pneumonia, and urinary tract infection but are rarely associated with liver abscess. Infections caused by ESBL-producing Enterobacteriaceae are particularly notorious for precipitating treatment failure and death. ESBL-producing Escherichia coli, particularly that producing the CTX-M type of ESBL, is an emerging pathogen and has become widespread since 2001 in both the United Kingdom and Europe (4, 5). The spread of E. coli-producing CTX-M-15 has involved β-lactamase transfer with the dissemination of blaCTX-M genes in both the general community and the hospital environment. In Asia, evolution of CTX-M-type β-lactamase genes from blaCTX-M-3 to blaCTX-M-15 under the selective pressure of antimicrobial therapy has occurred (6).

The pathogenesis of K. pneumoniae liver abscess is uncertain, although the capsular serotype K1/K2 seems likely involved, given the resistance of this serotype to phagocytosis and killing by neutrophils. Further studies are ongoing to elucidate the relationship between the virulence factors and resistant genes.

In conclusion, the presently reported case has shown that the strain of type CTX-M-15 ESBL-producing K. pneumoniae causing liver abscess differed from strains causing community-acquired liver abscess. Control of the spread of antibiotic-resistant bacteria such as ESBL-producing Enterobacteriaceae from the hospital environment to the general community is an important clinical and epidemiological concern. K. pneumoniae strains with ESBL-producing and virulence serotype K1 characteristics may be increasing in community-acquired liver abscess, complicating the management of the malady.


arrow
ACKNOWLEDGMENTS
 
This study was supported by grants from the Tri-Service General Hospital (TSGH-C95-50 and C95-51) and the National Science Council (NSC 95-2314-B-016-013).


arrow
FOOTNOTES
 
{triangledown} Published ahead of print on 3 December 2007. Back


arrow
REFERENCES
 
    1
  1. Chang, S. C., C. T. Fang, P. R. Hsueh, Y. C. Chen, and K. T. Luh. 2000. Klebsiella pneumoniae isolates causing liver abscess in Taiwan. Diagn. Microbiol. Infect. Dis. 37:279-284.[CrossRef][Medline]
    2. 2
  2. Eckert, C., V. Gautier, M. Saladin-Allard, N. Hidri, C. Verdet, Z. Ould-Hocine, G. Barnaud, F. Delisle, A. Rossier, T. Lambert, A. Philippon, and G. Arlet. 2004. Dissemination of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob. Agents Chemother. 48:1249-1255.[Abstract/Free Full Text]
    3. 3
  3. Fung, C. P., F. Y. Chang, S. C. Lee, B. S. Hu, B. I. Kuo, C. Y. Liu, M. Ho, and L. K. Siu. 2002. A global emerging disease of Klebsiella pneumoniae liver abscess: is serotype K1 an important factor for complicated endophthalmitis? Gut 50:420-424.[Abstract/Free Full Text]
    4. 4
  4. Jeong, S. H., I. K. Bae, S. B. Kwon, J. H. Lee, J. S. Song, H. I. Jung, K. H. Sung, S. J. Jang, and S. H. Lee. 2005. Dissemination of transferable CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli in Korea. J. Appl. Microbiol. 98:921-927.[CrossRef][Medline]
    5. 5
  5. Livermore, D. M., and P. M. Hawkey. 2005. CTX-M: changing the face of ESBLs in the UK. J. Antimicrob. Chemother. 56:451-454.[Abstract/Free Full Text]
    6. 6
  6. Mendonça, N., J. Leitão, V. Manageiro, E. Ferreira, the Antimicrobial Resistance Surveillance Program in Portugal, and M. Caniça. 2007. Spread of extended-spectrum beta-lactamase CTX-M-producing Escherichia coli clinical isolates in community and nosocomial environments in Portugal. Antimicrob. Agents Chemother. 51:1946-1955.[Abstract/Free Full Text]
Sheng-Chiang Su
Division of Infectious Diseases and Tropical Medicine
Department of Internal Medicine
Tri-Service General Hospital
National Defense Medical Center
Taipei, Taiwan

L. K. Siu
Ling Ma
Division of Clinical Research
National Health Research Institutes
Taipei, Taiwan

Kuo-Ming Yeh
Division of Infectious Diseases and Tropical Medicine
Department of Internal Medicine
Tri-Service General Hospital
National Defense Medical Center
Taipei, Taiwan

Chang-Phone Fung
National Yang-Ming University
Taipei, Taiwan

Jung-Chung Lin*
Feng-Yee Chang
Division of Infectious Diseases and Tropical Medicine
Department of Internal Medicine
Tri-Service General Hospital
National Defense Medical Center
Taipei, Taiwan

* Phone: 886 2 87927257, Fax: 886 2 87927258, Email: linjungchung1{at}yahoo.com.tw

Antimicrobial Agents and Chemotherapy, February 2008, p. 804-805, Vol. 52, No. 2
0066-4804/08/$08.00+0     doi:10.1128/AAC.01269-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Su, S.-C.
Right arrow Articles by Chang, F.-Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Su, S.-C.
Right arrow Articles by Chang, F.-Y.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»